We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

220 hedge funds and large institutions have $3.16B invested in Xenon Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 78 increasing their positions, 67 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

441% more call options, than puts

Call options by funds: $25.6M | Put options by funds: $4.73M

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

25% more capital inflows, than outflows

Capital inflows: $319M | Capital outflows: $255M

16% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 67

8% more funds holding

Funds holding: 204 → 220 (+16)

0.11% less ownership

Funds ownership: 97.53% → 97.42% (-0.11%)

29% less funds holding in top 10

Funds holding in top 10: 14 → 10 (-4)

Holders
220
Holders Change
+16
Holders Change %
+7.84%
% of All Funds
3.16%
Holding in Top 10
10
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-28.57%
% of All Funds
0.14%
New
35
Increased
78
Reduced
67
Closed
19
Calls
$25.6​M
Puts
$4.73​M
Net Calls
+$20.9​M
Net Calls Change
+$22.5​M

XENE Hedge Fund Activity: Q1 2024 in Review

220 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2024, worth a combined $3.16B — down 4.7% from $3.32B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new XENE positions and 19 closed out — a net gain of 16 holders — while 78 added to existing stakes and 67 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $43.5M. The largest seller was BVF Inc, exiting entirely with an estimated $41M sold.

  • 220 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2024, up from 204 in Q4 2023.
  • Funds reported $3.16B of Xenon Pharmaceuticals stock for Q1 2024, down 4.7% quarter-over-quarter.
  • 35 funds opened new Xenon Pharmaceuticals positions in Q1 2024 and 19 closed out, a net change of +16 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $43.5M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $41M sold.

Based on aggregated 13F filings for Q1 2024.